

Tim H BrÃ¼mmendorf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7026224/publications.pdf>

Version: 2024-02-01

300
papers

9,646
citations

53939

47
h-index

56606

87
g-index

307
all docs

307
docs citations

307
times ranked

12399
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> , 2022, 139, 87-103.	0.6	82
2	Differential impact of <i>IDH1</i>/<i>2</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	2.5	17
3	Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for <i>CSNK1A1</i> in clonal expansion. <i>Blood Advances</i> , 2022, 6, 1780-1796.	2.5	7
4	Antibody titers after SARS-CoV-2 mRNA vaccination in patients with aplastic anemiaâ€”A singleâ€”center study. <i>European Journal of Haematology</i> , 2022, 108, 528-531.	1.1	4
5	Novel homozygous nonsense mutation in the P5â€”Nâ€”1 coding gene as an alternative cause for hereditary anemia with basophilic stippling. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05501.	0.2	0
6	Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. <i>International Journal of Hematology</i> , 2022, 115, 838-851.	0.7	6
7	CRISPR/Cas9-engineered human ES cells harboring heterozygous and homozygous c-KIT knockout. <i>Stem Cell Research</i> , 2022, 60, 102732.	0.3	1
8	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. <i>Hematological Oncology</i> , 2022, 40, 491-504.	0.8	0
9	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	6.9	17
10	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. <i>Blood Reviews</i> , 2022, 56, 100968.	2.8	16
11	Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1). <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05766.	0.2	2
12	Analysis of automatically generated embedding guides for cell classification. , 2022, , .		0
13	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. <i>Leukemia</i> , 2022, 36, 1825-1833.	3.3	43
14	Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita. <i>British Journal of Haematology</i> , 2021, 193, 669-673.	1.2	20
15	Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. <i>Cell Stem Cell</i> , 2021, 28, 637-652.e8.	5.2	92
16	Targeting of BCR-ABL1 and IRE1Î± induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia. <i>Carcinogenesis</i> , 2021, 42, 272-284.	1.3	9
17	Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations â€” a registry based analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1432-1440.	0.6	7
18	Internetâ€”based patient survey on the consequences of COVIDâ€”19 lockdown on treatment and medical followâ€”up of patients with aplastic anemia or paroxysmal nocturnal hemoglobinuria in Germany. <i>European Journal of Haematology</i> , 2021, 106, 740-742.	1.1	0

#	ARTICLE	IF	CITATIONS
19	Cord blood telomere shortening associates with increased gestational age and birth weight in preterm neonates. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 344.	0.8	5
20	Longitudinal changes in telomere length in PCB-exposed individuals: interaction with CMV infection. <i>Archives of Toxicology</i> , 2021, 95, 1517-1520.	1.9	2
21	Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1361.	1.0	16
22	Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. <i>European Journal of Haematology</i> , 2021, 106, 808-820.	1.1	10
23	Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. <i>International Journal of Hematology</i> , 2021, 114, 65-78.	0.7	9
24	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 2095.	1.7	7
25	Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. <i>Blood</i> , 2021, 137, 2070-2084.	0.6	21
26	Surrounding Cell Suppression For Unsupervised Representation Learning In Hematological Cell Classification. , 2021, , .		0
27	Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 646883.	1.3	7
28	JAK2-V617F and interferon- γ induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. <i>Blood</i> , 2021, 137, 2139-2151.	0.6	26
29	Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies. <i>International Journal of Cancer</i> , 2021, 149, 1189-1198.	2.3	17
30	Treatment of telomeropathies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101282.	0.7	15
31	Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. <i>Cancers</i> , 2021, 13, 3145.	1.7	13
32	Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility. <i>European Journal of Haematology</i> , 2021, 107, 324-332.	1.1	3
33	The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN. <i>Cancers</i> , 2021, 13, 4210.	1.7	7
34	Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. <i>Cancers</i> , 2021, 13, 4086.	1.7	17
35	Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells. <i>Annals of Hematology</i> , 2021, 100, 2943-2956.	0.8	9
36	CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation. <i>Stem Cell Research</i> , 2021, 55, 102490.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias. <i>Leukemia Research</i> , 2021, 111, 106690.	0.4	12
38	Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 729207.	1.3	5
39	Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 3279-3289.	2.5	21
40	Epigenetic Clocks Are Not Accelerated in COVID-19 Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9306.	1.8	21
41	Successful allogeneic stem cell transplantation of a patient with Werner syndrome and acute myeloid leukemia. <i>Leukemia Research</i> , 2021, 108, 106609.	0.4	1
42	Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms. <i>Blood Advances</i> , 2021, 5, 3373-3376.	2.5	7
43	Comprehensive support for families with parental cancer (Family-SCOUT), evaluation of a complex intervention: study protocol for a non-randomized controlled trial. <i>Trials</i> , 2021, 22, 622.	0.7	7
44	Transient elastography in adult patients with cryptic dyskeratosis congenita reveals subclinical liver fibrosis: a retrospective analysis of the Aachen telomere biology disease registry. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 395.	1.2	3
45	Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN. <i>Leukemia Research</i> , 2021, 110, 106646.	0.4	2
46	CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes. <i>Stem Cell Reports</i> , 2021, 16, 2768-2783.	2.3	8
47	Human DC3 Antigen Presenting Dendritic Cells From Induced Pluripotent Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 667304.	1.8	2
48	Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients. <i>HemaSphere</i> , 2021, 5, e657.	1.2	2
49	Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response. <i>Blood</i> , 2021, 138, 3608-3608.	0.6	3
50	Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Beyond Trial. <i>Blood</i> , 2021, 138, 1475-1475.	0.6	5
51	Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial. <i>Blood</i> , 2021, 138, 4637-4637.	0.6	0
52	The Unfolded Protein Response Mediates Resistance in AML and Its Therapeutic Targeting Enhances TKI Induced Cell Death in FLT3-ITD + AML. <i>Blood</i> , 2021, 138, 2246-2246.	0.6	1
53	Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit. <i>Blood</i> , 2021, 138, 1242-1242.	0.6	0
54	LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia. <i>Molecular Carcinogenesis</i> , 2020, 59, 87-103.	1.3	11

#	ARTICLE	IF	CITATIONS
55	Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. <i>Leukemia</i> , 2020, 34, 1062-1074.	3.3	42
56	Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies. <i>Annals of the New York Academy of Sciences</i> , 2020, 1466, 93-103.	1.8	35
57	Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7196.	1.8	18
58	Systematic Analysis And Automated Search Of Hyper-Parameters For Cell Classifier Training. , 2020, , .		3
59	Therapeutic inhibition of Fc γ RIIb signaling targets leukemic stem cells in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2635-2647.	3.3	8
60	Circular Anchors for the Detection of Hematopoietic Cells Using Retinanet. , 2020, , .		12
61	Dexamethasone nanomedicines for COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 622-624.	15.6	138
62	Pregnancy outcomes in patients treated with bosutinib. <i>International Journal of Hematologic Oncology</i> , 2020, 9, IJH26.	0.7	17
63	PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation. <i>Clinical Epigenetics</i> , 2020, 12, 125.	1.8	20
64	Revesz syndrome revisited. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 299.	1.2	13
65	Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2020, 135, 1548-1559.	0.6	58
66	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e228-e231.	1.7	29
67	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. <i>Leukemia</i> , 2020, 34, 2074-2086.	3.3	50
68	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. <i>Leukemia</i> , 2020, 34, 2125-2137.	3.3	47
69	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020, 136, 823-830.	0.6	85
70	Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. <i>European Journal of Haematology</i> , 2020, 105, 655-658.	1.1	24
71	Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1241-1249.	0.8	9
72	Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRASG12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS. <i>Blood</i> , 2020, 136, 47-48.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype. <i>Blood</i> , 2020, 136, 41-42.	0.6	0
74	Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia. <i>BMC Cancer</i> , 2019, 19, 658.	1.1	12
75	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. <i>Oncolimmunology</i> , 2019, 8, e1638210.	2.1	19
76	Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S290.	0.2	0
77	Tracking myeloid malignancies by targeted analysis of successive DNA methylation at neighboring CG dinucleotides. <i>Haematologica</i> , 2019, 104, e349-e351.	1.7	9
78	Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)â€”a report on phase III. <i>Annals of Hematology</i> , 2019, 98, 1547-1559.	0.8	18
79	Effects of continuous high-dose G-CSF administration on hematopoietic stem cell mobilization and telomere length in patients with amyotrophic lateral sclerosis â€” a pilot study. <i>Cytokine</i> , 2019, 120, 192-201.	1.4	6
80	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1589-1599.	1.2	21
81	Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. <i>Leukemia</i> , 2019, 33, 1964-1977.	3.3	35
82	Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). <i>Annals of Hematology</i> , 2019, 98, 1393-1401.	0.8	10
83	Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha. <i>Journal of Hematology and Oncology</i> , 2019, 12, 36.	6.9	19
84	Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2019, 98, 2703-2709.	0.8	3
85	Validity of RECIST Version 1.1 for Response Assessment in Metastatic Cancer: A Prospective, Multireader Study. <i>Radiology</i> , 2019, 290, 349-356.	3.6	58
86	Characterization of acute myeloid leukemia with del(9q) â€” Impact of the genes in the minimally deleted region. <i>Leukemia Research</i> , 2019, 76, 15-23.	0.4	16
87	JAK2V617F but not CALR mutations confer increased molecular responses to interferon-Î± via JAK1/STAT1 activation. <i>Leukemia</i> , 2019, 33, 995-1010.	3.3	43
88	The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. <i>Blood</i> , 2019, 133, 550-565.	0.6	57
89	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. <i>Haematologica</i> , 2019, 104, 955-962.	1.7	18
90	Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study. <i>Blood</i> , 2019, 134, 1650-1650.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 13-13.	0.6	16
92	High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels. <i>Blood</i> , 2019, 134, 666-666.	0.6	2
93	Nilotinib Vs Nilotinib Plus Pegylated Interferon $\hat{\pm}$ (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response. <i>Blood</i> , 2019, 134, 495-495.	0.6	13
94	Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 4157-4157.	0.6	1
95	Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1647-1647.	0.6	3
96	Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 2944-2944.	0.6	2
97	Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level. <i>Blood</i> , 2019, 134, 559-559.	0.6	0
98	STAT1 Transcriptional Response Predicts Molecular Responses of PB-Derived Clonogenic Cells from MPN Patients to Interferon Alpha. <i>Blood</i> , 2019, 134, 1679-1679.	0.6	1
99	Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study. <i>Blood</i> , 2019, 134, 2936-2936.	0.6	0
100	Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. <i>Leukemia</i> , 2018, 32, 1762-1767.	3.3	27
101	Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. <i>Annals of Oncology</i> , 2018, 29, 578-587.	0.6	26
102	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , The, 2018, 19, 747-757.	5.1	444
103	Elimination of different leukaemia subtypes using novel <scp>CD</scp>89-specific human cytolytic fusion proteins. <i>British Journal of Haematology</i> , 2018, 183, 313-317.	1.2	7
104	Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. <i>Cancer</i> , 2018, 124, 587-595.	2.0	19
105	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 231-237.	0.8	356
106	Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells. <i>PLoS ONE</i> , 2018, 13, e0197233.	1.1	5
107	Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 608.	1.8	9
108	Bosutinib in chronic myeloid leukemia: patient selection and perspectives. <i>Journal of Blood Medicine</i> , 2018, Volume 9, 43-50.	0.7	17

#	ARTICLE	IF	CITATIONS
109	Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 1572-1579.	2.5	24
110	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. <i>Haematologica</i> , 2018, 103, 1298-1307.	1.7	49
111	<sc>CD</sc>57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated <sc>PI</sc>3 kinase delta syndrome. <i>Immunology and Cell Biology</i> , 2018, 96, 1060-1071.	1.0	29
112	Germ line predisposition to myeloid malignancies appearing in adulthood. <i>Expert Review of Hematology</i> , 2018, 11, 625-636.	1.0	5
113	Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor. <i>Recent Results in Cancer Research</i> , 2018, 212, 87-108.	1.8	5
114	Comprehensive characterization of chorionic villi-derived mesenchymal stromal cells from human placenta. <i>Stem Cell Research and Therapy</i> , 2018, 9, 28.	2.4	38
115	Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALRâ€“MPLâ€“JAK2â€“STAT5 pathway. <i>Leukemia</i> , 2018, 32, 2087-2090.	3.3	7
116	Influence of Telomere Length in Hepatocytes on Liver Regeneration after Partial Hepatectomy in Rats. <i>European Surgical Research</i> , 2018, 59, 83-90.	0.6	3
117	Impact of Diarrhea on Health-Related Quality of Life: Analysis of the Phase 3 BFORE Trial of Bosutinib Vs Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2018, 132, 4264-4264.	0.6	2
118	Pregnancy Outcomes in Patients Treated with Bosutinib. <i>Blood</i> , 2018, 132, 1729-1729.	0.6	6
119	Synergistic Dual Inhibition of BCR-ABL1 and the Unfolded Protein Response Causes p38 MAPK-Mediated Cell Death and Sensitizes BCR-ABL1+ Acute Lymphoblastic Leukemia to Dexamethasone. <i>Blood</i> , 2018, 132, 4674-4674.	0.6	2
120	Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. <i>Blood</i> , 2018, 132, 460-460.	0.6	6
121	Implication of Hypoxia-Inducible Factor-1 (HIF-1) As a New Therapeutic Target in JAK2V617F Positive Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2018, 132, 4318-4318.	0.6	1
122	EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1528-1528.	0.6	1
123	Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT). <i>Blood</i> , 2018, 132, 1979-1979.	0.6	1
124	Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1461-1461.	0.6	3
125	Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita. <i>Blood</i> , 2018, 132, 2585-2585.	0.6	1
126	Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7002-7002.	0.8	13

#	ARTICLE	IF	CITATIONS
127	Characterization of Hematopoietic Differentiation Profiles of MPN Patient-Derived Inducible Pluripotent Stem Cells Harboring Homozygous Vs Heterozygous Calreticulin Mutations. <i>Blood</i> , 2018, 132, 3065-3065.	0.6	0
128	Role of hnRNP K and Interacting mRNAs in Pathogenesis of AML with 9q Deletion. <i>Blood</i> , 2018, 132, 1531-1531.	0.6	0
129	Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN). <i>Blood</i> , 2018, 132, 4292-4292.	0.6	0
130	Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible. <i>Blood</i> , 2018, 132, 5176-5176.	0.6	0
131	Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC). <i>Blood</i> , 2018, 132, 3861-3861.	0.6	0
132	Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta. <i>Blood</i> , 2018, 132, 4320-4320.	0.6	0
133	Accelerated telomere shortening in peripheral blood lymphocytes after occupational polychlorinated biphenyls exposure. <i>Archives of Toxicology</i> , 2017, 91, 289-300.	1.9	48
134	Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)â€”report on phases I and II. <i>Annals of Hematology</i> , 2017, 96, 171-181.	0.8	25
135	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 684-695.e6.	0.2	42
136	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1585-1596.	1.2	29
137	P2.03b-036 Analysis of Potentially Targetable Mutations in 821 Patients with Squamous cell Lung Cancer Undergoing Routine NGS-Based Molecular Diagnostics. <i>Journal of Thoracic Oncology</i> , 2017, 12, S956-S957.	0.5	0
138	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1543-1554.	1.2	20
139	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. <i>Annals of Hematology</i> , 2017, 96, 887-894.	0.8	7
140	Building a National Framework for Adolescent and Young Adult Hematology and Oncology and Transition from Pediatric to Adult Care: Report of the Inaugural Meeting of the â€œAJETâ€•Working Group of the German Society for Pediatric Oncology and Hematology. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 194-199.	0.7	11
141	Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 664-670.	0.2	4
142	Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 1457-1461.	0.8	18
143	Patients with acute myelogenous leukemia (AML) from a socially disadvantaged environment show poorer therapeutic outcome. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2017, 25, 187-195.	0.8	0
144	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitorâ€”Sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2289-2300.	3.2	38

#	ARTICLE	IF	CITATIONS
145	Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. <i>Blood</i> , 2017, 130, 900-900.	0.6	9
146	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. <i>Oncotarget</i> , 2017, 8, 43915-43924.	0.8	12
147	The SCLT α BCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients. <i>Oncotarget</i> , 2017, 8, 34736-34749.	0.8	4
148	A high BMI is a risk factor in younger patients with <i>de novo</i> acute myelogenous leukemia. <i>European Journal of Haematology</i> , 2016, 97, 17-24.	1.1	21
149	Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. <i>American Journal of Hematology</i> , 2016, 91, 606-616.	2.0	76
150	Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. <i>Journal of Hematology and Oncology</i> , 2016, 9, 45.	6.9	72
151	A three-gene expression-based risk score can refine the European LeukemiaNet AML classification. <i>Journal of Hematology and Oncology</i> , 2016, 9, 78.	6.9	21
152	Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia. <i>Scientific Reports</i> , 2016, 6, 24057.	1.6	8
153	Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. <i>British Journal of Haematology</i> , 2016, 172, 97-110.	1.2	41
154	Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. <i>American Journal of Hematology</i> , 2016, 91, 1206-1214.	2.0	90
155	An engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sites. <i>Journal of Hematology and Oncology</i> , 2016, 9, 4.	6.9	35
156	Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. <i>Nature Medicine</i> , 2016, 22, 288-297.	15.2	191
157	Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). <i>Annals of Hematology</i> , 2016, 95, 707-718.	0.8	32
158	LPS-stimulated human bone marrow stroma cells support myeloid cell development and progenitor cell maintenance. <i>Annals of Hematology</i> , 2016, 95, 173-178.	0.8	33
159	Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1921-1921.	0.6	4
160	CD64-directed microtubule associated protein tau kills leukemic blasts <i>ex vivo</i> . <i>Oncotarget</i> , 2016, 7, 67166-67174.	0.8	10
161	DNA methylation in <i>PRDM8</i> is indicative for dyskeratosis congenita. <i>Oncotarget</i> , 2016, 7, 10765-10772.	0.8	15
162	Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment. <i>Blood</i> , 2016, 128, 3069-3069.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase. <i>Blood</i> , 2016, 128, 4243-4243.	0.6	0
164	Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML. <i>Blood</i> , 2016, 128, 1885-1885.	0.6	0
165	HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens. <i>Blood</i> , 2016, 128, 2169-2169.	0.6	0
166	Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8+ and CD4+ T Cell-Epitopes for Immunotherapeutic Approaches. <i>Blood</i> , 2016, 128, 4232-4232.	0.6	1
167	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. <i>Blood</i> , 2016, 128, 2815-2815.	0.6	1
168	Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes. <i>Blood</i> , 2016, 128, 4260-4260.	0.6	0
169	Telomere shortening in enterocytes of patients with uncontrolled acute intestinal graft-versus-host disease. <i>Blood</i> , 2015, 126, 2518-2521.	0.6	19
170	Early-onset Evans syndrome, immunodeficiency, and premature immunosenescence associated with tripeptidyl-peptidase II deficiency. <i>Blood</i> , 2015, 125, 753-761.	0.6	66
171	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. <i>Haematologica</i> , 2015, 100, 205-213.	1.7	20
172	Angptl4 is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 64.	6.9	23
173	DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2015, 7, 116.	1.8	16
174	Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. <i>PLoS ONE</i> , 2015, 10, e0123476.	1.1	12
175	MicroRNAs and Metabolites in Serum Change after Chemotherapy: Impact on Hematopoietic Stem and Progenitor Cells. <i>PLoS ONE</i> , 2015, 10, e0128231.	1.1	8
176	Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2015, 90, 755-768.	2.0	72
177	Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1575-1586.	2.0	11
178	Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers. <i>Journal of Proteomics</i> , 2015, 119, 218-229.	1.2	29
179	JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. <i>Cancer Research</i> , 2015, 75, 2187-2199.	0.4	163
180	MicroRNA expression profiles of serum from patients before and after chemotherapy. <i>Genomics Data</i> , 2015, 6, 125-127.	1.3	7

#	ARTICLE	IF	CITATIONS
181	Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide. <i>Leukemia Research</i> , 2015, 39, 1292-1298.	0.4	15
182	Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. <i>British Journal of Haematology</i> , 2015, 168, 69-81.	1.2	177
183	Comprehensive Genomic Analysis Provides Further Evidence That Iron Overload Can Induce Genetic Instability in Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 2842-2842.	0.6	13
184	Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial. <i>Blood</i> , 2015, 126, 599-599.	0.6	7
185	Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0125783.	1.1	23
186	A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition. <i>Aging</i> , 2015, 7, 911-927.	1.4	13
187	Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions. <i>ELife</i> , 2015, 4, .	2.8	81
188	A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease. <i>Blood</i> , 2015, 126, 15-15.	0.6	0
189	Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. <i>Blood</i> , 2015, 126, 315-315.	0.6	0
190	Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib. <i>Blood</i> , 2015, 126, 4041-4041.	0.6	0
191	BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1569-1569.	0.6	0
192	A novel mouse model for inhibition of DOHH mediated hypusine modification reveals crucial function for embryonic development, proliferation and oncogenic transformation. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 963-76.	1.2	46
193	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	2.0	102
194	Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms. <i>Journal of Hematology and Oncology</i> , 2014, 7, 92.	6.9	29
195	Target Lesion Selection. <i>Investigative Radiology</i> , 2014, 49, 509-517.	3.5	27
196	Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. <i>Drug Discovery Today: Technologies</i> , 2014, 11, 89-99.	4.0	65
197	Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines. <i>Journal of Proteomics</i> , 2014, 96, 300-313.	1.2	14
198	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. <i>Blood</i> , 2014, 123, 1309-1318.	0.6	124

#	ARTICLE	IF	CITATIONS
199	Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 947-953.	2.0	98
200	Genetic characterization of acquired aplastic anemia by targeted sequencing. <i>Haematologica</i> , 2014, 99, e165-e167.	1.7	51
201	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i> , 2014, 123, 2317-2324.	0.6	167
202	Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor. <i>Recent Results in Cancer Research</i> , 2014, 201, 81-97.	1.8	18
203	Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3969-3969.	0.6	1
204	Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology. <i>Blood</i> , 2014, 124, 4528-4528.	0.6	1
205	Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj 5544-5544.	0.6	4
206	Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP) Tj ETQq0 0 0 rgBT /Overlock 10 Tj 5544-5544.	0.6	1
207	Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7060-7060.	0.8	6
208	Prevention of psychosocial morbidity and improvement of coping strategies: Effects of a cancer patient and caregiver centred information series.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20566-e20566.	0.8	0
209	Novel Deletion Mutants in the Juxtamembrane Domain of Fms-like Tyrosine Kinase 3 (FLT3) Induce Transformation By Release from Autoinhibition in AML. <i>Blood</i> , 2014, 124, 885-885.	0.6	0
210	HLA Ligandome Analysis in Primary Polycythemia Vera (PV) Samples Shows No Tumor-Association of Naturally Presented JAK2 Ligands but Reveals a Vast Array of Novel PV-Associated HLA Ligands. <i>Blood</i> , 2014, 124, 4581-4581.	0.6	0
211	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014, 124, 4512-4512.	0.6	1
212	The JAK Inhibitor Ruxolitinib Substantially Affects NK Cells in MPN Patients. <i>Blood</i> , 2014, 124, 3169-3169.	0.6	0
213	Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL). <i>Blood</i> , 2014, 124, 946-946.	0.6	4
214	Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia (CML)â€”Towards Peptide Based Immunotherapy. <i>Blood</i> , 2014, 124, 4518-4518.	0.6	1
215	The 3-OH Derivative of the Polychlorinated Biphenyl (PCB)-28 Inhibits Telomerase Expression and Accelerates Telomere Shortening in Vitro: A Rationale for the Significantly Shortened Telomere Length Found in Peripheral Blood Lymphocytes of Workers Exposed to High Doses of Lower Chlorinated PCBs. <i>Blood</i> . 2014. 124. 4139-4139.	0.6	0
216	Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study. <i>Leukemia Research</i> , 2013, 37, 900-906.	0.4	22

#	ARTICLE	IF	CITATIONS
217	Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2013, 31, 1207-1216.	1.2	32
218	Pluripotent stem cells escape from senescence-associated DNA methylation changes. <i>Genome Research</i> , 2013, 23, 248-259.	2.4	107
219	Age-Associated DNA Methylation Signature Reveals Premature Aging In Patients With Aplastic Anemia and Dyskeratosis Congenita Which Correlates With Telomere Shortening. <i>Blood</i> , 2013, 122, 1223-1223.	0.6	2
220	Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML. <i>Blood</i> , 2013, 122, 1484-1484.	0.6	1
221	Development Of a Disease Specific Quality Of Life Questionnaire For Patients With Aplastic Anemia and/Or Paroxysmal Nocturnal Hemoglobinuria (QLQ-AA/PNH). <i>Blood</i> , 2013, 122, 1680-1680.	0.6	2
222	Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update. <i>Blood</i> , 2013, 122, 2723-2723.	0.6	4
223	HLA Ligandome Analysis Of Chronic Myeloid Leukemia (CML), Revealed Novel Tumor Associated Antigens For Peptide Based Immunotherapy. <i>Blood</i> , 2013, 122, 3975-3975.	0.6	2
224	Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update. <i>Blood</i> , 2013, 122, 4025-4025.	0.6	1
225	Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study. <i>Blood</i> , 2013, 122, 4030-4030.	0.6	3
226	Combination of a Proteomics Approach and Reengineering of Meso Scale Network Models for Prediction of Mode-of-Action for Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2013, 8, e53668.	1.1	7
227	Genetic Characterization Of Aplastic Anemia Patients By Targeted Sequencing. <i>Blood</i> , 2013, 122, 2470-2470.	0.6	0
228	BCR-ABL Cooperates With a Telomere-Associated Secretory Phenotype (TASP) To Facilitate Malignant Proliferation Of Hematopoietic Stem Cells. <i>Blood</i> , 2013, 122, 3976-3976.	0.6	0
229	Telomere Length Of Granulocytes Significantly Increases During The First Six Months Of Lenalidomide Treatment In Patients With Isolated 5q- Syndrome. <i>Blood</i> , 2013, 122, 2781-2781.	0.6	0
230	Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1469-1469.	0.6	0
231	Angptl-4 Is Upregulated Under Inflammatory Conditions In The BM Of Mice, Expands Myeloid Progenitors and Accelerates Reconstitution Of Platelets After Myelosuppressive Therapy. <i>Blood</i> , 2013, 122, 3677-3677.	0.6	0
232	Telomere Shortening At Diagnosis Of Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Is Significantly More Pronounced In Patients With Less-Than-Optimal Versus Optimal Molecular Response (ELN criteria) After 12 Months Of Treatment With Nilotinib. <i>Blood</i> , 2013, 122, 1471-1471.	0.6	0
233	Enterocytes Of Patients With Uncontrolled Acute Graft Versus Host Disease Of The Gut Undergo Massive Telomere Shortening Compared To Unaffected Controls. <i>Blood</i> , 2013, 122, 4467-4467.	0.6	0
234	Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model. <i>Clinical Cancer Research</i> , 2012, 18, 4621-4632.	3.2	34

#	ARTICLE	IF	CITATIONS
235	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. <i>Blood</i> , 2012, 119, 3403-3412.	0.6	281
236	Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias. <i>Investigational New Drugs</i> , 2012, 30, 2274-2283.	1.2	9
237	Peroxiredoxins 3 and 4 Are Overexpressed in Prostate Cancer Tissue and Affect the Proliferation of Prostate Cancer Cells in Vitro. <i>Journal of Proteome Research</i> , 2012, 11, 2452-2466.	1.8	46
238	Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3486-3492.	0.8	404
239	Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia. <i>Thrombosis and Haemostasis</i> , 2012, 108, 397-398.	1.8	12
240	Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1121-1127.	1.1	19
241	Protein-protein-interaction Network Organization of the Hypusine Modification System. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1289-1305.	2.5	15
242	Quantitative analyses of <i>DAPK1</i> methylation in AML and MDS. <i>International Journal of Cancer</i> , 2012, 131, E138-42.	2.3	34
243	Nilotinib, imatinib, and telomere homeostasis disruption in chronic myeloid leukemia. <i>Cancer</i> , 2012, 118, 5183-5183.	2.0	0
244	Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. <i>Annals of Hematology</i> , 2012, 91, 1115-1120.	0.8	51
245	Prognostic role of microRNA polymorphisms in advanced gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10552-10552.	0.8	0
246	Serum after Autologous Transplantation Stimulates Proliferation and Expansion of Human Hematopoietic Progenitor Cells. <i>PLoS ONE</i> , 2011, 6, e18012.	1.1	11
247	Dynamics of Resistance Development to Imatinib under Increasing Selection Pressure: A Combination of Mathematical Models and In Vitro Data. <i>PLoS ONE</i> , 2011, 6, e28955.	1.1	15
248	Array-based DNA methylation profiling in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2011, 155, 65-72.	1.2	21
249	Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells. <i>Experimental Hematology</i> , 2011, 39, 66-76.e2.	0.2	29
250	Loss or Inhibition of Stromal-Derived PIGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. <i>Cancer Cell</i> , 2011, 19, 740-753.	7.7	124
251	Identification of CD133 ⁺ /Telomerase ^{low} Progenitor Cells in Glioblastoma-Derived Cancer Stem Cell Lines. <i>Cellular and Molecular Neurobiology</i> , 2011, 31, 337-343.	1.7	20
252	Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2011, 2, 419-423.	1.8	21

#	ARTICLE	IF	CITATIONS
253	<i>In vivo</i> efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA ² in a human acute myeloid leukemia xenograft tumor model. <i>International Journal of Cancer</i> , 2011, 129, 1277-1282.	2.3	32
254	Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. <i>Epigenetics</i> , 2011, 6, 1047-1052.	1.3	23
255	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. <i>Blood</i> , 2011, 118, 4567-4576.	0.6	406
256	Forced Activation of β -Catenin Signaling Supports the Transformation of hTERT-Immortalized Human Fetal Hepatocytes. <i>Molecular Cancer Research</i> , 2011, 9, 1222-1231.	1.5	16
257	Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform. <i>PLoS ONE</i> , 2011, 6, e16833.	1.1	67
258	Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro. <i>PLoS ONE</i> , 2011, 6, e19164.	1.1	39
259	Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 1647-1655.	0.4	33
260	Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. <i>Histopathology</i> , 2010, 57, 418-426.	1.6	30
261	Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 56-64.	3.2	119
262	Danusertib (formerly PHA-739358) - A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor. <i>Recent Results in Cancer Research</i> , 2010, 184, 199-214.	1.8	44
263	Bosutinib. <i>Recent Results in Cancer Research</i> , 2010, 184, 119-127.	1.8	21
264	Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 551-558.	0.6	16
265	Novel KRIT1 Mutation and No Molecular Evidence of Anticipation in a Family with Cerebral and Spinal Cavernous Malformations. <i>European Neurology</i> , 2009, 61, 154-158.	0.6	12
266	Accelerated Telomere Shortening in Leukocyte Subpopulations of Patients With Coronary Heart Disease. <i>Circulation</i> , 2009, 120, 1364-1372.	1.6	128
267	Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. <i>Hematological Oncology</i> , 2009, 27, 123-129.	0.8	39
268	Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2009, 2, 489-497.	1.0	32
269	Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed In Vitro by Combination Treatment with Imatinib. <i>Blood</i> , 2009, 114, 1724-1724.	0.6	1
270	Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. <i>Annals of Hematology</i> , 2008, 87, 451-457.	0.8	85

#	ARTICLE	IF	CITATIONS
271	PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. <i>Leukemia Research</i> , 2008, 32, 1857-1865.	0.4	18
272	Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. <i>Blood</i> , 2008, 111, 4355-4364.	0.6	163
273	Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL ⁺ positive leukemias identified by a proteomics approach. <i>Blood</i> , 2007, 109, 1701-1711.	0.6	89
274	Absence of oncogenic transformation despite acquisition of cytogenetic aberrations in long-term cultured telomerase-immortalized human fetal hepatocytes. <i>Cancer Letters</i> , 2007, 256, 120-127.	3.2	8
275	Aprotinin-associated hemolytic thrombotic microangiopathy in a patient with acute myelogenous leukemia (AML) and systemic coagulopathy. <i>American Journal of Hematology</i> , 2007, 82, 1122-1124.	2.0	7
276	Concise Review: Telomere Biology in Normal and Leukemic Hematopoietic Stem Cells. <i>Stem Cells</i> , 2007, 25, 1853-1861.	1.4	55
277	Safe Use of Oxaliplatin in a Patient with Metastatic Breast Cancer and Combined Renal and Hepatic Failure*. <i>Oncology Research and Treatment</i> , 2006, 29, 273-275.	0.8	6
278	BCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia. <i>Cancer Research</i> , 2006, 66, 5892-5900.	0.4	29
279	A case of pulmonary carcinosarcoma (squamous cell carcinoma and osteosarcoma) treated with cisplatin and doxorubicin. <i>Anticancer Research</i> , 2006, 26, 3893-7.	0.5	14
280	Accelerated telomere shortening in glycosylphosphatidylinositol (GPI) ⁻ negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH. <i>Blood</i> , 2005, 106, 531-533.	0.6	37
281	Effect of Tyrosine Kinase Inhibition Using Imatinib on Normal Lymphohematopoietic Cells. <i>Annals of the New York Academy of Sciences</i> , 2005, 1044, 168-177.	1.8	11
282	Clonal Heterogeneity in Growth Kinetics of CD34+CD38 ⁻ Human Cord Blood Cells In Vitro Is Correlated with Gene Expression Pattern and Telomere Length. <i>Stem Cells</i> , 2005, 23, 946-957.	1.4	25
283	Effects of Imatinib on Normal Hematopoiesis and Immune Activation. <i>Stem Cells</i> , 2005, 23, 1082-1088.	1.4	76
284	Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. <i>Experimental Hematology</i> , 2005, 33, 542-549.	0.2	13
285	Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor- κ B and Akt Signaling Pathways. <i>Clinical Cancer Research</i> , 2005, 11, 1928-1940.	3.2	74
286	Telomerase Activity ^{is} a Prognostic Factor in Colorectal Cancer?. <i>Oncology Research and Treatment</i> , 2005, 28, 550-551.	0.8	1
287	Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. <i>Haematologica</i> , 2005, 90, 307-16.	1.7	68
288	Telomere length analysis by fluorescence in situ hybridization and flow cytometry (Flow-FISH)/Telomerlängen-Messung mittels Fluoreszenz-in-situ-Hybridisierung und Durchflusssyztometrie (Flow-FISH). <i>Laboratoriums Medizin</i> , 2004, 28, 307-316.	0.1	0

#	ARTICLE	IF	CITATIONS
289	CDCP1 Identifies a Broad Spectrum of Normal and Malignant Stem/Progenitor Cell Subsets of Hematopoietic and Nonhematopoietic Origin. <i>Stem Cells</i> , 2004, 22, 334-343.	1.4	70
290	Telomere length and telomerase activity during expansion and differentiation of human mesenchymal stem cells and chondrocytes. <i>Journal of Molecular Medicine</i> , 2004, 82, 49-55.	1.7	120
291	Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. <i>Blood</i> , 2004, 103, 538-544.	0.6	156
292	Inhibitory effect of imatinib on normal progenitor cells in vitro. <i>Blood</i> , 2004, 103, 523-529.	0.6	97
293	Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia. <i>Annals of the New York Academy of Sciences</i> , 2003, 996, 26-38.	1.8	28
294	Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. <i>Blood</i> , 2003, 101, 375-375.	0.6	27
295	Longitudinal studies of telomere length in feline blood cells. <i>Experimental Hematology</i> , 2002, 30, 1147-1152.	0.2	70
296	Limited Telomere Shortening in Hematopoietic Stem Cells after Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2001, 938, 1-8.	1.8	31
297	Telomere Length Dynamics in Normal Individuals and in Patients with Hematopoietic Stem Cell-Associated Disorders. <i>Annals of the New York Academy of Sciences</i> , 2001, 938, 293-304.	1.8	73
298	Telomere Length Dynamics in Normal and Malignant Hematopoiesis. <i>Rejuvenation Research</i> , 2000, 3, 397-409.	0.2	3
299	Telomere Fluorescence Measurements in Granulocytes and T Lymphocyte Subsets Point to a High Turnover of Hematopoietic Stem Cells and Memory T Cells in Early Childhood. <i>Journal of Experimental Medicine</i> , 1999, 190, 157-168.	4.2	611
300	Asymmetric Cell Divisions in Hematopoietic Stem Cells. <i>Annals of the New York Academy of Sciences</i> , 1999, 872, 265-273.	1.8	13